JESÚS ARENA WIEDFELDT
We are mostly a specialized medical product wholesaler with a strong supply chain presence across the country, enabling us to easily reach a majority of the population. In addition, we provide diverse logistical services for the transportation of specialized medical products.
Innovation, quality of service, and ethics management are the cornerstones of MAYPO, allowing us to compete in the market and always provide high-quality and expert services to our customers.
The pharmaceutical industry is becoming more and more specialized every day—in terms of technology—and this will allow the circulation of high-quality products in an efficient distribution system as well as more targeted service customers.
SECRET TO SUCCESS
In 2011 the Bayer group celebrated 90 years in Mexico. I think that the secret to our success is our long-standing presence in the market and our own production facilities here in Mexico.
Our business here is about 55% healthcare, 33% material science—mostly polymers and polycarbonates—and more than 10% crop science, which includes the business units of crop protection, bioscience, and environmental science.
Bayer generally introduces products to all of its markets as quickly as possible; we don’t have an approach of first launching products in Europe, and then only years later bringing them to other markets.
Mexico is not a means to an end, but it is a gateway. There are two reasons for this: the size of the market, and the influence Mexico has on many countries across Latin America. We are usually an early adopter and a trendsetter in terms of treatment options and clinical research.
We study diseases in-depth in order to understand their pathways. We identify where to stop the disease or how to delay its progress. Once we decide which pathway to interfere in, then we decide the best modality approach.
My aspiration is for Amgen to become the number one biopharmaceutical firm in Mexico. My commitment to achieve this is defined by being able to give as many patients as possible access to our medicines.
PABLO ESCANDON CUSI
We are moving ahead by providing the traditional wholesale service of delivering pharmaceutical goods and health and beauty aid products not only to drugstores, but also to hospitals and medical centers.
We are experiencing strong performance based on the development of new products and services and innovative approaches to our client needs, which is positioning us very favorably in the eyes of both manufacturers and retailers.
The government has been focused on developing infrastructure and services to create a strong demand for generics, a market that is growing fast with a very strong base. Mexico is late in coming into this segment, and the generic market is still relatively small compared to other places such as the US, Canada, and Europe.
We are the number one company in bringing in new products to the market worldwide and also to Mexico, and this is thanks to the new compounds and medicines we are introducing
MORE THAN BEFORE
Science is moving toward biotech products more than just the traditional chemical compounds. It is a big part of the pipeline for all companies, including Novartis.
We are seeing very good signs from the government to again put resources into new products. We believe that we will see growth happening in the next five to eight years in Mexico, and Novartis will be very successful.
© The Business Year